A single-arm, open-label, phase II study of ruxolitinib plus azacitidine in patients with myelofibrosis demonstrated a more than a 50% reduction in palpable spleen length in 62% of patients at 24 weeks, with 95% maintaining this at 48 weeks. In addition, at 24 months, bone marrow reticulin fibrosis grade improved in 57% of patients.
HemOnc Today